Dupixent, a medication used to treat several diseases such as atopic dermatitis and asthma, saw a significant increase in sales during the fourth quarter of 2020. According to the financial results released by Sanofi and Regeneron Pharmaceuticals, the companies that co-develop and co-market Dupixent, the drug's sales reached $1.35 billion in Q4 2020, representing a 35% increase compared to the same period in 2019 [1].
The strong sales performance of Dupixent was driven by its growing usage in both the United States and other regions. In the United States, Dupixent's sales reached $1.05 billion in Q4 2020, a 33% increase from Q4 2019. Meanwhile, international sales of Dupixent amounted to $297 million in Q4 2020, a 41% increase from the same period in 2019 [1].
The robust sales growth of Dupixent can be attributed to its increasing adoption in the treatment of various medical conditions. In November 2020, the U.S. Food and Drug Administration (FDA) approved Dupixent for the treatment of chronic rhinosinusitis with nasal polyps, which expanded the drug's potential market [2].
It is worth noting that Dupixent's patent protection is set to expire in 2026, which may lead to the entry of generic competitors and potentially impact its sales [3]. However, the drug's strong sales performance in Q4 2020 indicates that it remains a valuable product for Sanofi and Regeneron Pharmaceuticals.
In summary, Dupixent's sales reached $1.35 billion in Q4 2020, a 35% increase from Q4 2019, driven by its growing usage in both the United States and other regions. The drug's sales growth was driven by its expanding indications and increasing adoption in the treatment of various medical conditions.
Sources:
1. Sanofi and Regeneron Pharmaceuticals. (2021). Full-year 2020 Sales and Business Update. <https://www.regeneron.com/sites/default/files/Regeneron_4Q_2020_Earnings_Release.pdf>
2. U.S. Food and Drug Administration. (2020). FDA Approves Dupixent (dupilumab) for Treatment of Nasal Polyps. <https://www.fda.gov/news-events/press-announcements/fda-approves-dupixent-dupilumab-treatment-nasal-polyps>
3. DrugPatentWatch. (n.d.). Dupixent (dupilumab) Patent Expiration & Generics. <https://www.drugpatentwatch.com/patent/dupixent-dupilumab-US-9248263-B2/>